Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adj...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Bear, Harry D, Tang, Gong, Rastogi, Priya, Geyer, Charles E, Liu, Qing, Robidoux, André, Baez-Diaz, Luis, Brufsky, Adam M, Mehta, Rita S, Fehrenbacher, Louis, Young, James A, Senecal, Francis M, Gaur, Rakesh, Margolese, Richard G, Adams, Paul T, Gross, Howard M, Costantino, Joseph P, Paik, Soonmyung, Swain, Sandra M, Mamounas, Eleftherios P, Wolmark, Norman
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624323/
https://ncbi.nlm.nih.gov/pubmed/26272770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00041-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados